Skip to content

US · INCR · DRUG MANUFACTURERS - SPECIALTY & GENERIC

InterCure Ltd. (INCR) intrinsic value and stock valuation

$3.24as of 2026-11-21 · Mkt cap 58.04M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

InterCure Ltd. DCF and intrinsic value

InvestorsCraft values INCR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from INCR’s statements →

InterCure Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Herzliya, TA 4676670 intercure.co

How the business is doing

Fiscal 2011–2025, USD

Revenue
$270.2M+33% 5y CAGRd
20112025
Net income
-$-35.71M
20112025
Free cash flow
$13.3M
20112025
Total equity
$396.4M+6.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$270.2M$238.8M$355.6M$388.7M$219.7M
Operating income$6.73M-$-67.21M-$-41.57M$50.6M$28.2M
Net income-$-35.71M-$-67.8M-$-61.96M$44.8M$4.69M
EPSd-$-628.7K-$-1.42M-$-1.36M$988.3K$114.8K
Operating cash flow$16.8M-$-66.93M-$-53.63M$51.3M$25M
Capital expenditure-$-3.55M-$-4.38M-$-2.62M-$-19.74M-$-14.03M
Free cash flow$13.3M-$-71.3M-$-56.25M$31.5M$11M
Total assets$690.6M$762.6M$786.6M$958M$686.3M
Total debt$183M$211.4M$195.7M$255.2M$108.9M
Net debt$136.6M$133.1M$94.5M$22.6M-$-87.31M
Total equity$396.4M$397.7M$457.1M$521.5M$459.2M
Cash and short-term investments$46.7M$78.7M$101.3M$232.8M$196.6M
Income statement
20252024202320222021
Revenue$270.2M$238.8M$355.6M$388.7M$219.7M
Cost of revenue$237M$208.6M$250.5M$233.6M$128.6M
Gross profit$33.2M$30.2M$105.1M$155.1M$91.1M
Research and development expenses$390K$410K$390K$630K$1.24M
Selling, general and administrative expenses$80.4M$84.6M$86.2M$97.3M$53.5M
Other expenses-$-54.35M$12.4M$60M$6.51M$8.25M
Operating expenses$26.5M$97.4M$146.7M$104.5M$63M
Cost and expenses$263.5M$306.1M$397.1M$338.1M$191.5M
Interest income$1.55M$2.7M$4.55M$840K$130K
Interest expense$19.7M$20.6M$24.2M$14.7M$5.04M
Depreciation and amortization$17.2M$15.4M$13.2M$11.7M$7.39M
Ebitda-$-7.29M-$-51.31M-$-23.9M$70.2M$31.2M
Operating income$6.73M-$-67.21M-$-41.57M$50.6M$28.2M
Total other income/expenses, net-$-50.84M-$-20.11M-$-19.72M-$-6.79M-$-9.45M
Income before tax-$-44.1M-$-87.32M-$-61.28M$43.8M$18.7M
Income tax expense-$-7.32M-$-14.53M$2.25M$90K$11.4M
Net income-$-35.71M-$-67.8M-$-61.96M$44.8M$4.69M
Weighted average shares outstanding$56.8M$47.8M$45.6M$45.4M$38.5M
Weighted average diluted shares outstanding$56.8M$47.8M$45.6M$45.4M$40.8M
Balance sheet
20252024202320222021
Cash and short-term investments$46.7M$78.7M$101.3M$232.8M$196.6M
Net receivables$154.5M$180.5M$61.1M$49.5M$37.5M
Inventory$108.1M$125.3M$106.3M$146.5M$67.9M
Total current assets$316.8M$391.8M$418.8M$527.5M$336.2M
Property, plant and equipment, net$102.8M$105.2M$97.5M$103.1M$86.5M
Goodwill and intangible assets$219.2M$224.6M$221.1M$284.2M$258.1M
Long-term investments$1.02M$2.15M$1.92M$42.6M$2.56M
Total non-current assets$373.8M$370.8M$367.8M$450.5M$350.2M
Total assets$690.6M$762.6M$786.6M$958M$686.3M
Accounts payable$68.1M$77.5M$78.4M$126.1M$64.5M
Short-term debt$104.1M$74.2M$92.8M$132.4M$75.6M
Deferred revenue$0.00$0.00$0.00$8.06M$2.9M
Total current liabilities$214.4M$226.8M$225.9M$312.7M$193.6M
Long-term debt$79M$137.2M$102.8M$122.8M$33.3M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$79.8M$138.2M$103.7M$123.8M$33.6M
Capital lease obligations$23.8M$28M$25.3M$27.5M$24.7M
Total liabilities$294.2M$364.9M$329.6M$436.5M$227.1M
Common stock$675.6M$658.6M$643.2M$632M$623.6M
Retained earnings-$-314.62M-$-277.58M-$-204M-$-141.65M-$-186.47M
Accumulated other comprehensive income (loss)$16M$16M$16M$2.39M$2.39M
Total equity$396.4M$397.7M$457.1M$521.5M$459.2M
Total investments$1.23M$2.48M$2.11M$42.8M$2.9M
Total debt$183M$211.4M$195.7M$255.2M$108.9M
Net debt$136.6M$133.1M$94.5M$22.6M-$-87.31M
Cash flow statement
20252024202320222021
Net income-$-36.78M-$-72.79M-$-63.53M$43.8M$7.29M
Depreciation and amortization$17.2M$15.4M$13.2M$11.7M$7.39M
Stock-based compensation$2.43M$2.28M$2.59M$8.91M$6.45M
Change in working capital$18.9M-$-9.19M-$-43.55M-$-3.02M-$-1.65M
Accounts receivable$9.29M$13.3M-$-23.49M-$-18.29M$8.39M
Inventory$16M-$-17.44M$40.2M-$-75.99M-$-17.89M
Accounts payable-$-8.82M-$-8.9M-$-47.63M$57M$2.79M
Net cash provided by operating activities$16.8M-$-66.93M-$-53.63M$51.3M$25M
Investments in property, plant and equipment-$-3.55M-$-4.38M-$-2.62M-$-19.74M-$-14.03M
Acquisitions, net$1.67M$410K-$-4.2M-$-8.32M-$-19.09M
Net cash used for investing activities-$-1.99M$17.7M$4.77M-$-142.5M-$-65.21M
Common stock issued$1.5M$34M$0.00$0.00$128.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-46.66M$26.5M-$-82.89M$120.5M$197.9M
Net change in cash-$-31.85M-$-22.82M-$-131.45M$36.4M$158.3M
Cash at end of period$46.5M$78.3M$101.1M$232.6M$196.2M
Operating cash flow$16.8M-$-66.93M-$-53.63M$51.3M$25M
Capital expenditure-$-3.55M-$-4.38M-$-2.62M-$-19.74M-$-14.03M
Free cash flow$13.3M-$-71.3M-$-56.25M$31.5M$11M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About InterCure Ltd.

        InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel.

        CEO
        Alexander Rabinovich
        Employees
        285
        Beta
        0.57

        Explore

        Frequently asked questions

        What is the intrinsic value of InterCure Ltd. (INCR)?

        InterCure Ltd. (INCR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is INCR undervalued?

        INCR trades at a price of $3.24 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.